Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma
Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved..
Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
---|---|
Enthalten in: |
Actas dermo-sifiliograficas - 112(2021), 4 vom: 15. Apr., Seite 295-301 |
Sprache: |
Englisch |
---|
Weiterer Titel: |
Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado |
---|
Beteiligte Personen: |
Sanmartín, O [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 24.06.2021 Date Revised 24.06.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ad.2020.11.002 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM317648195 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM317648195 | ||
003 | DE-627 | ||
005 | 20231225163713.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ad.2020.11.002 |2 doi | |
028 | 5 | 2 | |a pubmed24n1058.xml |
035 | |a (DE-627)NLM317648195 | ||
035 | |a (NLM)33197438 | ||
035 | |a (PII)S0001-7310(20)30471-3 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sanmartín, O |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma |
246 | 3 | 3 | |a Sonidegib en el tratamiento del carcinoma basocelular localmente avanzado |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.06.2021 | ||
500 | |a Date Revised 24.06.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
520 | |a Sonidegib is an antagonist of the transmembrane protein Smoothened in the Hedgehog signaling pathway. It is indicated for the treatment of locally advanced basal cell carcinoma (BCC) that is not amenable to curative surgery or radiotherapy. Sonidegib's efficacy and safety were demonstrated in the phase 2 BOLT trial, where 61% (95% CI, 48-72%) of patients with locally advanced BCC treated with sonidegib 200 mg achieved an objective response to treatment with a mean time to response of 4 months. The median duration of response was 26.1 months and the median progression-free survival was 22.1 months. The most common adverse events were muscle spasms (54.4%), hair loss (49.4%), and loss of taste (44.3%); most events were grade 1 or 2. In this review, we summarize the main findings on the efficacy, safety, and tolerability of sonidegib and discuss the management of locally advanced BCC with this drug | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Carcinoma basocelular localmente avanzado | |
650 | 4 | |a Hedgehog pathway inhibitors | |
650 | 4 | |a Hedgehog signaling pathway | |
650 | 4 | |a Inhibidores de la vía Hedgehog | |
650 | 4 | |a Locally advanced basal cell carcinoma | |
650 | 4 | |a Sonidegib | |
650 | 4 | |a Vía de señalización Hedgehog | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Biphenyl Compounds |2 NLM | |
650 | 7 | |a Hedgehog Proteins |2 NLM | |
650 | 7 | |a Pyridines |2 NLM | |
650 | 7 | |a sonidegib |2 NLM | |
650 | 7 | |a 0RLU3VTK5M |2 NLM | |
700 | 1 | |a Llombart, B |e verfasserin |4 aut | |
700 | 1 | |a Carretero Hernández, G |e verfasserin |4 aut | |
700 | 1 | |a Flórez Menéndez, Á |e verfasserin |4 aut | |
700 | 1 | |a Botella-Estrada, R |e verfasserin |4 aut | |
700 | 1 | |a Herrera Ceballos, E |e verfasserin |4 aut | |
700 | 1 | |a Puig, S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Actas dermo-sifiliograficas |d 2011 |g 112(2021), 4 vom: 15. Apr., Seite 295-301 |w (DE-627)NLM205627536 |x 2173-5778 |7 nnns |
773 | 1 | 8 | |g volume:112 |g year:2021 |g number:4 |g day:15 |g month:04 |g pages:295-301 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ad.2020.11.002 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 112 |j 2021 |e 4 |b 15 |c 04 |h 295-301 |